Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
Steigende Produktionsmengen, operative Hebelwirkung und der Goldpreis könnten zusammen neue Impulse setzen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
271 Leser
Artikel bewerten:
(1)

Stock Day Media: Panacea Life Sciences Holdings, Inc. Chief Scientific Officer, Dr. James Baumgartner, is Featured on The Stock Day Podcast

PHOENIX, AZ / ACCESSWIRE / July 18, 2023 /Phoenix, Arizona The Stock Day Podcast welcomed Panacea Life Sciences Holdings, Inc. (PLSH)("the Company"), a holding company structured to develop and facilitate manufacturing, research, product development and distribution in the high-growth, natural human and animal health & wellness market segment. Chief Scientific Officer, James Baumgartner, PhD, joined Stock Day host Kevin Davis.

Davis began the interview by asking about the Company's background and current projects. "Panacea Life Sciences is a health and wellness company," said Dr. Baumgartner. "We started off as an industrial hemp cannabinoid company and what we've been doing is harnessing our manufacturing capabilities for soft gels, liquid fills, and topical lotions to make products that are going to benefit people's everyday health," he shared. "This ranges from cannabinoid medications and dietary supplements, as well as unique skin moisturizers."

"Could you tell me more about your company's expansion into the mushroom market?", asked Davis. "Functional mushrooms are extraordinarily fascinating," said Dr. Baumgartner. "The mushroom market is divided into three segments: functional mushrooms, schedule one mushrooms, which contain psilocybin, and the Amanita Muscaria mushroom," he explained. "We've been looking at each one of these spaces in terms of developing new products to help people with specific conditions or needs."

"How do mushrooms serve as dietary supplements?", asked Davis. "One of the active compounds in mushrooms is called beta-glucan," said Dr. Baumgartner, before elaborating on different types of mushrooms and their applications, which can include improved memory, immune function, gut health, and exercise performance and endurance.

"Could you elaborate on the Amanita Muscaria mushroom?", asked Davis. "This is the Super Mario mushroom that is seen all over the place," said Dr. Baumgartner, adding that it can be easily identified by its red color and white dots. "This mushroom has intoxicating properties," he said, noting that the mushroom has been used historically for visions and healing properties. "The active component that produces a euphoric feeling and intoxication is called muscimol," said Dr. Baumgartner. "At smaller doses, this is a great sleep inducer and at larger doses it will create a euphoric high."

"We also think this compound may help to improve anxiety and could be useful for those experiencing mild forms of PTSD and depression," continued Dr. Baumgartner. "Those are things that we are taking a look at in terms of developing things into meaningful products."

"How is Panacea working to develop these new sources for dietary supplements?", asked Davis. "We have a collaboration with Colorado State University to develop analytical methods to measure the active components of each one of these mushroom species," said Dr. Baumgartner, adding that this process also allows the company to identify high levels of heavy metals in the mushrooms. "By developing these methods with CSU, we can enter dietary supplement clinical trials."

"The second thing that we are doing is blending different natural ingredients together to create a better product," shared Dr. Baumgartner, adding that the Company is working with performance and endurance enhancing compounds and blending them with ingredients like ginseng to further improve athletic performance.

To close the interview, Dr. Baumgartner encouraged listeners and shareholders to keep up-to-date on the Company's current and upcoming projects as they continue to expand their portfolio of cannabinoid and mushroom-based products in the health and wellness industry.

To hear the entire interview with Dr. James Baumgartner, follow the link to the podcast here: https://audioboom.com/posts/8336605-panacea-life-sciences-holdings-inc-chief-scientific-officer-dr-james-baumgartner-is-featured

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About Panacea Life Sciences Holdings, Inc.

Panacea Life Sciences Holdings, Inc. (PLSH) is a holding company structured to develop and facilitate manufacturing, research, product development and distribution in the high-growth, natural human and animal health & wellness market segment. Its subsidiary, Panacea Life Sciences, Inc. (PLS) is a woman-founded and led company dedicated to manufacturing, distribution, research and production of the highest-quality nutraceutical, cannabinoid, mushroom, kratom and other natural, plant-based ingredients and products. PLS operates out of a 51,000 square foot, state-of-the-art, cGMP facility in Golden Colorado. If you would like more information, please visit www.panacealife.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, risks arising from supply chain disruptions or our ability to obtain raw materials as well as similar problems with our vendors, our ability to fulfill purchase orders on a timely manner, our ability to fully collect money for our purchase orders, the risk of customers returning our products, impact of the pandemic including new variants on our workforce, as well as those risks and uncertainties described by us in our annual report on Form 10-K for the fiscal year ended December 31, 2022 under the heading "Risk Factors". Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.

Contact:

info@panacealife.com
800-985-0515

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

Stock Day Media
StockDayMedia.Com
(602) 821-1102

SOURCE: Stock Day Media

View source version on accesswire.com:
https://www.accesswire.com/768848/Panacea-Life-Sciences-Holdings-Inc-Chief-Scientific-Officer-Dr-James-Baumgartner-is-Featured-on-The-Stock-Day-Podcast

© 2023 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.